NeuroPace Q1 revenue rises 20%, beats estimates, raises 2026 outlook

NeuroPace

12/05/2026 21:18

Overview

U.S. epilepsy device maker's Q1 revenue rose 20% yr/yr, beating analyst expectations

Company raised 2026 revenue guidance to $99 mln-$101 mln from $98 mln-$100 mln

Q1 net loss widened slightly to $6.7 mln from $6.6 mln a year ago

Outlook

NeuroPace raises 2026 revenue guidance to $99 mln-$101 mln from $98 mln-$100 mln

Company expects 21%-23% growth in core RNS revenue, excluding IGE indication expansion

NeuroPace continues to expect IGE contribution following potential NAUTILUS PMA-S approval in mid-2026

Result Drivers

RNS SYSTEM SALES - Revenue growth was primarily driven by increased sales of the RNS System

MANUFACTURING AND PRICING - Improved manufacturing efficiency and higher average selling prices contributed to gross margin performance

COMMERCIAL EXPANSION - Higher sales and marketing expenses reflected ongoing scaling of commercial activities and investment in direct-to-consumer marketing

Company press release: ID:nBwJBLPka

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$22.07 mln
$21.64 mln (8 Analysts)
Q1 EPS
-$0.20
Q1 Net Income
-$6.69 mln
Q1 Gross Profit
$18.05 mln
Q1 Income from Operations
-$5.57 mln
Q1 Operating Expenses
$23.62 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Neuropace Inc is $20.00, about 27.6% above its May 11 closing price of $15.67

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)